Boston Sci Says It Will Be Careful About Resorbable Scaffold Investment
This article was originally published in The Gray Sheet
Executive Summary
The company announced July 20 the start of its 30-patient, single-arm FAST study assessing its everolimus-eluting scaffold system, but executives says Boston Scientific will be closely considering whether the system warrants long-term investment, considering the promise of its Synergy stent.
You may also be interested in...
Absorbing Debate: Boston Sci, Abbott Differ On Whether The Future Of Stents Is To Disappear
Competing visions of the future of percutaneous coronary interventions were on display at TCT year, with Boston Scientific pushing its Synergy bioabsorbable polymer-coated, drug-eluting metal stent platform as the better long-term option to fully-resorbable scaffolds of the type Abbott is first out of the gate with.
Boston Scientific Expects Synergy To Dominate Drug-Eluting Stents In US
Boston Scientific wants to expand the lead against other stents used by interventional cardiologists with the launch of its bioabsorbable Synergy drug-eluting stent. The company expects it will become the workhorse of the industry to handle a broad range of surgeries to treat coronary artery disease.
Absorbing Debate: Boston Sci, Abbott Differ On Whether The Future Of Stents Is To Disappear
Competing visions of the future of percutaneous coronary interventions were on display at TCT year, with Boston Scientific pushing its Synergy bioabsorbable polymer-coated, drug-eluting metal stent platform as the better long-term option to fully-resorbable scaffolds of the type Abbott is first out of the gate with.